OMERS ADMINISTRATION Corp boosted its stake in Danaher Co. (NYSE:DHR - Free Report) by 74.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,202 shares of the conglomerate's stock after acquiring an additional 21,397 shares during the period. OMERS ADMINISTRATION Corp's holdings in Danaher were worth $11,524,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Gilbert & Cook Inc. boosted its stake in Danaher by 2.5% during the fourth quarter. Gilbert & Cook Inc. now owns 1,749 shares of the conglomerate's stock worth $401,000 after acquiring an additional 42 shares in the last quarter. Grimes & Company Inc. boosted its position in shares of Danaher by 0.6% during the 4th quarter. Grimes & Company Inc. now owns 7,390 shares of the conglomerate's stock worth $1,696,000 after purchasing an additional 43 shares in the last quarter. Dakota Community Bank & Trust NA grew its stake in shares of Danaher by 16.4% in the 4th quarter. Dakota Community Bank & Trust NA now owns 320 shares of the conglomerate's stock valued at $73,000 after buying an additional 45 shares during the period. Spinnaker Trust increased its position in Danaher by 1.2% in the 4th quarter. Spinnaker Trust now owns 4,304 shares of the conglomerate's stock valued at $988,000 after buying an additional 50 shares in the last quarter. Finally, Fortis Capital Advisors LLC boosted its holdings in Danaher by 1.3% in the fourth quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock worth $914,000 after acquiring an additional 50 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on DHR shares. Raymond James reaffirmed a "market perform" rating on shares of Danaher in a research report on Monday, February 3rd. Barclays increased their price objective on shares of Danaher from $205.00 to $215.00 and gave the company an "overweight" rating in a research note on Tuesday, April 22nd. StockNews.com upgraded Danaher from a "hold" rating to a "buy" rating in a research note on Monday. Wells Fargo & Company decreased their target price on Danaher from $280.00 to $240.00 and set an "equal weight" rating for the company in a research report on Thursday, January 30th. Finally, Guggenheim reaffirmed a "buy" rating and set a $250.00 price target on shares of Danaher in a research report on Wednesday, April 23rd. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to MarketBeat, Danaher presently has a consensus rating of "Moderate Buy" and an average target price of $264.40.
Check Out Our Latest Research Report on Danaher
Danaher Price Performance
DHR stock traded up $5.08 during midday trading on Friday, reaching $196.03. The company had a trading volume of 3,868,501 shares, compared to its average volume of 3,453,040. The firm has a 50-day moving average price of $197.06 and a 200-day moving average price of $217.96. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The company has a market capitalization of $140.29 billion, a P/E ratio of 37.13, a P/E/G ratio of 2.66 and a beta of 0.80. Danaher Co. has a 1 year low of $171.00 and a 1 year high of $281.70.
Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.26. Danaher had a return on equity of 10.82% and a net margin of 16.33%. The business had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.58 billion. On average, research analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current fiscal year.
Danaher Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.65%. Danaher's dividend payout ratio is presently 24.85%.
Insider Buying and Selling at Danaher
In related news, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the transaction, the executive vice president now owns 15,179 shares in the company, valued at $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the sale, the chairman now owns 3,105,808 shares in the company, valued at $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.10% of the company's stock.
Danaher Company Profile
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
